Remote Patient Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The Remote Patient Monitoring Market is set to reach USD 39.06 billion in 2031, growing at a CAGR of 21.63% between 2026 and 2031, from USD 14.65 billion in 2026.

Key Highlights

Market Overview

The Remote Patient Monitoring (RPM) Market is anticipated to grow at a significant CAGR of 21.63% during the forecast period 2026–2031. The market is growing rapidly as healthcare systems continue moving towards digitally connected, patient-centric care models that extend clinical monitoring beyond traditional hospital settings. RPM solutions provide continuous monitoring of physiological parameters, such as blood pressure, glucose levels, oxygen saturation, ECG/heart rate, respiratory rate, and body temperature. They use wearable sensors, connected medical devices, cloud computing, and artificial intelligence (AI), together with interoperable electronic health record (EHR) platforms. These applications contribute to improved care coordination, real-time clinical decision-making, and the shift toward value-based healthcare delivery.

The strategy of expanding connected care ecosystems through integrated AI-enabled monitoring platforms, interoperability improvements, successful acquisitions and partnerships by major industry leaders such as Koninklijke Philips N.V., GE HealthCare, Medtronic, Abbott, Dexcom, and Biofourmis is also promoting market expansion.

• Adoption of digital health continues to grow across the globe. According to the World Health Organization (WHO), over 120 countries have established or are developing their national digital health strategies to reinforce healthcare delivery, interoperability, telehealth, and connected patient monitoring, which act as an enabling landscape for RPM deployment.

• Interoperability is becoming a major aspect of the patient monitoring ecosystem for healthcare technology companies. In September 2025, Philips expanded its strategic partnership with Masimo to incorporate leading-edge monitoring technologies, including SET pulse oximetry and Radius PPG into Philips' next-generation patient-monitoring platforms. This partnership will fast-track the development of interoperable monitoring solutions to support both hospital-based and remote patient care.

• The US continues strengthening reimbursement for remote monitoring services. In the CY 2026 Medicare Physician Fee Schedule Proposed Rule, the Centers for Medicare & Medicaid Services (CMS) submitted some key updates that support digital healthcare delivery. They proposed continued reimbursement for remote physiologic and therapeutic monitoring, providing opportunities for providers to adopt connected care technologies.

• The European Health Data Space (EHDS) Regulation, which was adopted in 2025, aims to enable secure cross-border access and interoperability of electronic health data across EU member states, which will support wider adoption of connected health technologies and RPM solutions.

• The deployment of RPM platforms in healthcare systems supports the need for continuous patient engagement, personalized treatment pathways, scheduled post-discharge follow-up, and coordinated multidisciplinary care. This ultimately leads to better healthcare outcomes by providing more efficient healthcare delivery.

• The growing investment in cloud-based monitoring platforms, advanced analytics-enabled clinical decision support systems, and integrated virtual care solutions worldwide will also contribute to the rise in the RPM market in the coming years.

Market Drivers

Rising Burden of Chronic Diseases and Aging Population

Chronic diseases, along with rapid population aging, have become one of the strongest growth drivers for the remote patient monitoring market. Remote patient monitoring solutions are increasingly being embraced by healthcare providers to facilitate continuous physiological monitoring, alert clinical staff to any signs of early clinical deterioration to prevent avoidable hospitalizations, and manage patients with illnesses in the long term.

• Noncommunicable diseases (NCDs) account for an estimated 75% of global deaths, with cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes being the most common causes, as per the World Health Organisation (WHO). This generates high demand for uninterrupted remote patient monitoring.

• According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, 589 million adults aged 20–79 years were estimated to suffer from diabetes in 2025, and the number is predicted to account for 853 million by 2050. This is expected to increase adoption of continuous glucose monitoring and remote diabetes management platforms globally.

• According to the WHO, by 2050, there will be 2.1 billion people aged over 60 years globally compared with 1.4 billion in 2030, and the proportion of people aged over 60 is projected to nearly double from around 12% in 2015 to almost one quarter of the global population by 2050, leading towards an increased demand for continuous remote patient monitoring and home-care options.

• Rapidly rising clinical focus on early detection of patient deterioration, ongoing monitoring post hospital discharge, and long-term management of chronic diseases is propelling healthcare providers to adopt AI-based remote patient monitoring solutions that enable real-time intervention, minimize readmissions, and enhance patient health outcomes.

Major Segment Analysis

Glucose Monitors

By Device Type, the Remote Patient Monitoring Market is segmented into vital signs monitors, glucose monitors, blood pressure monitors, heart rate monitors, ECG monitors, Respiratory monitors, weight scales, pulse oximeters, and others.

Glucose monitors and ECG monitors are witnessing the fastest growth owing to the rising prevalence of diabetes and cardiovascular diseases. At the same time, blood pressure monitors and pulse oximeters continue to account for a significant market share due to their widespread use in hypertension management, chronic disease monitoring, and post-acute care. Meanwhile, wearable heart rate monitors and connected vital signs monitoring devices are gaining traction as healthcare providers increasingly focus on preventive care, early disease detection, and home-based patient management. The Glucose Monitors segment is growing significantly as continuous glucose monitoring (CGM) systems and wearable cardiac monitoring solutions become increasingly integrated with telemedicine platforms and electronic health records (EHRs).

• In the remote patient monitoring market, the glucose monitor segment is expected to command the overwhelming majority of the market, owing to its three primary sub-components, which are wearable subcutaneous sensors, reusable or integrated wireless transmitters, and digital display interface software.

• The glucose monitor segment is driven by the increasing global prevalence of diabetes and the transition towards value-based and home-centered healthcare. These devices are essential as they enable continuous or periodic monitoring of blood glucose levels, allowing healthcare providers to remotely track patients and intervene promptly when abnormal readings are detected.

• The rising growth in diabetes is regarded as a major primary growth driver. According to the International Diabetes Federation, the total number of adults with diabetes is predicted to rise to 853 million by 2050 from 589 million in 2024. The growing patient pool has significantly increased the demand for remote glucose monitoring solutions.

• Government initiatives and reimbursement policies in countries such as the United States, Germany, the United Kingdom, Japan, and Australia have accelerated the adoption of remote glucose monitoring, particularly for patients with Type 1 and insulin-dependent Type 2 diabetes. Expansion of telehealth reimbursement since the COVID-19 pandemic has further strengthened the market’s demand.

Homecare Settings

Based on end-user, the remote patient monitoring market is segmented into hospitals and clinics, ambulatory care centers, homecare settings, and others. The homecare setting is expected to show considerable growth owing to the aging population.

Advancements in healthcare infrastructure have amplified the market outlook for remote patient monitoring in hospitals and clinics. Transition towards connected and wireless monitoring approaches for patients has provided new growth prospects. The homecare settings segment is projected to show considerable growth fueled by the growing emphasis on cost-effective monitoring solutions for continuous tracking.

• High chronic disease prevalence, followed by an aging global population, has amplified conditions like hypertension, COPD, diabetes, and heart failure, thereby increasing the demand for continuous monitoring of patients outside hospitals. According to the WHO, the global population aged 60 years and above will reach 1.4 billion by 2030 and 2.1 billion by 2050.

• Growing technological shift has provided new market opportunities, with efforts made to integrate remote patient monitoring with AI analytics and EHR systems. Firms like Johnson & Johnson are investing in exploring AI-based RPM for cancer patients.

• Ongoing product innovation such as “Philips Virtual Care Management,” which offers scalable solutions supporting strong patient engagement, has provided new growth prospects for RPM usage in home care settings.

• Similarly, strategic collaborations such as GE Healthcare with Biofourmis and smartQare BV with Cuviva AB to transform patient monitoring in home settings are supporting market developments.

• Policies supporting RPM coverage, such as Medicare in the USA, have established a framework for RPM registration, which has made it more accessible for patients. Likewise, adoption of new payment models in EU nations has also supported market trajectory. For instance, the Netherlands provides telemonitoring reimbursement under “Code 039133” defined by the Dutch Healthcare Authority (NZa).

Regional Analysis

North America: the US

• Technological maturity of the United States has enabled adoption of modern approaches featuring wireless sensors and devices in healthcare for patient monitoring. The “AI Action Plan” launched by the government outlines strategies for AI adoption in healthcare, which will provide new market prospects.

• Progression in chronic disease prevalence followed by growing demand for effective patient treatment has further escalated the requirement for continuous monitoring scenarios, which is propelling the RPM market outlook in the USA.

• Acute nursing shortage in the USA has also accelerated the requirement for modern approaches, which has positively impacted the RPM market scope. According to the “Nursing Workforce Projections, 2023-2028” issued by HRSA, it projects a shortage of 267,300 registered nurses by 2028.

  Report Metric	Details
  Study Period	2021 to 2031
  Historical Data	2021 to 2024
  Base Year	2025
  Forecast Period	2026 – 2031
  Segmentation	Component, Application, End User, Geography
  Companies	Koninklijke Philips N.V. Abbott Laboratories GE Healthcare Technologies Inc. Boston Scientific Corporation Biotronik SE & Co. KG

• Presence of major market players like Philips, which, through their telemetry platform, are addressing the healthcare staff shortage in the USA, is driving market innovations. Similarly, innovative product launches like custom maternal RPM kits by Tenovi have supported market developments.

• Broad RPM coverage provided via Medicare, followed by establishment of RPM Codes by Centers for Medicare & Medicaid Services (CMS), has increased access for remote patient monitoring in the USA.

• Recently, CMS under its “2026 Physician Fee Schedule (PFS)” issued two new codes, “CPT99445” and “CPT 99470,” that further support reimbursement for short durations.

Company Profiles

Abbott Laboratories’ strategy in the remote patient monitoring (RPM) market focuses on developing connected, patient-centric digital health ecosystems focused on high-prevalence chronic conditions, such as cardiovascular disease and diabetes. By embedding low-power sensors, micro-electronics, and direct Bluetooth connectivity into both wearable and implantable devices, Abbott seamlessly bridges the gap between daily home life and clinical management.

Its core objective is to shift healthcare from reactive crisis management to proactive, value-based care by providing real-time data streaming directly to smartphones and cloud-based clinician portals like LibreView and myMerlin.

Key Developments

• 2026: Abbott, regarded as a global healthcare leader, announced that it secured a CE Market for the world’s first dual glucose-ketone sensing technology for those with diabetes.

• 2026: Abbott Laboratories expanded its Instinct continuous glucose monitoring sensor across Europe as part of its MiniMed Insulin pump systems. This expansion/integration is essential as it brings Abbott’s CGM technology directly into new automated insulin delivery platforms for diabetes patients.

• 2025: Abbott announced that it entered into a first-of-its-kind agreement to integrate data from its world-leading Libre CGM systems directly into Epic’s electronic health record systems in the U.S. This collaboration aims to improve the workflow efficiency for providers through Epic’s Aura Software.

Remote Patient Monitoring Market Scope: